

AMENDMENT

In the Claims:

✓ ✓ ✓
Please cancel Claims 62, and 78-87.

Please amend the pending claims as follows:

B¹
36. (Amended) A polyamine derivative, or salt thereof, wherein said derivative has the formula R_1-X-R_2 ,

wherein R_1-X- is of the formula $R-NH-CR'R''-CO-$,

wherein $-NH-CR'R''-CO-$ is a D- or L- form of valine, asparagine, or glutamine, or the D- form of lysine or arginine;

wherein R'' is H, CH_3 , CH_2CH_3 , or CHF_2 ;

wherein R is H or a head group selected from the group consisting of a straight or branched C_{1-10} aliphatic, alicyclic, single or multiring aromatic, single or multiring aryl substituted aliphatic, aliphatic-substituted single or multiring aromatic, a single or multiring heterocyclic, a single or multiring heterocyclic-substituted aliphatic and an aliphatic-substituted aromatic; and

wherein R_2 is a polyamine.

60. (Amended) A method comprising contacting a cell with a polyamine derivative or salt thereof, wherein said derivative has the formula R_1-X-R_2 ,

wherein R_1-X- is of the formula $R-NH-CR'R''-CO-$,

wherein $-NH-CR'R''-CO-$ is the L- form of lysine or arginine;

wherein R'' is H, CH_3 , CH_2CH_3 , or CHF_2 ;

B²
wherein R is H or a head group selected from the group consisting of a straight or branched C_{1-10} aliphatic, alicyclic, single or multiring aromatic, single or multiring aryl substituted aliphatic, aliphatic-substituted single or multiring aromatic, a single or multiring

B²
concl'd
heterocyclic, a single or multiring heterocyclic-substituted aliphatic and an aliphatic-substituted aromatic; and R₂ is a polyamine
under conditions such that polyamine transport in said cell is inhibited.

✓
Please add the following new claims:

88. The method of claim 60 or 61, wherein said contacting further comprises contacting said cell with a polyamine synthesis inhibitor.

89. The method of claim 88, wherein said polyamine synthesis inhibitor is α -difluoromethylornithine.

90. The method of claim 88 wherein said cell is in a subject with a disease or condition associated with undesired cell proliferation.

B³
91. The method of claim 89 wherein said cell is in a subject with a disease or condition associated with undesired cell proliferation.

92. The method of claim 90 wherein said undesired cell proliferation is associated with cancer.

93. The method of claim 91 wherein said undesired cell proliferation is associated with cancer.

94. The method of claim 54 wherein said undesired cell proliferation is associated with cancer.

95. The method of claim 63 wherein said undesired cell proliferation is associated with cancer.
